Zantac Lawsuit


Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Showing posts with label Paxil Protest. Show all posts
Showing posts with label Paxil Protest. Show all posts

Sunday, November 06, 2011

GlaxoSmithKline - The "Maladaptive" Company



There are many people/organisations that I greatly admire for their part in creating awareness in this minefield of deceit and fraud associated with the Seroxat scandal. Bloggers that have stood the test of time, Seroxat Secrets and GSK Licence To Kill have been at the forefront of spreading awareness about the dangers of Seroxat and the less than honest approach of it's manufacturer, GlaxoSmithKline.

Then we have support groups such as The Seroxat User Group, whose owner hasn't even taken Seroxat but sees there is a huge problem and has striven to help expose that problem through her advocacy work.

There's also been people like Alison Bass, Evelyn Pringle, Shelley Jofre, three journalists who have put their careers on the line, all of whom have, at one time or another, exposed the failings of GlaxoSmithKline and the regulatory systems, namely the MHRA and the FDA.

I've great admiration for the parents of both Sharise Gatchell and Sara Carlin, two teen who both took their own lives after being prescribed Seroxat. The strength of their parents to expose that dangers of Seroxat has given me strength over the years I have known them.

Charles Medawar for his tireless work in showing how the MHRA showed utter contempt for Seroxat Sufferers also deserves a mention, as do Prof David Healy, Peter Breggin and Joseph Glenmullen.

Attorney's in the US whom have shown dogged determination to get to the truth include The Tracy Law Firm, Donald J. Farber, Baum, Hedlund, Aristei & Goldman

There are many more, some I've met in person, others I hope to meet someday.

One such person is Rob Robinson, an activist who, with balls of steel, took the fight right to the doorstep of GlaxoSmithKline. If there was any justice in this world Rob, along with the aforementioned would be commended by their respective governments for exposing the dirty deeds of the UK's biggest pharmaceutical company.

The author of the Seroxat Secrets website recently posted about the recent $3 billion fine imposed on GlaxoSmithKline, the biggest fine in history to settle United States government civil and criminal investigations into its sales practices for numerous drugs. Seroxat Secrets wrote:


$3 billion – yes that’s record – but still no prison time.

It strikes me there are a couple of points coming out of this story:

1 – it seems if you have enough money you can buy your way out of trouble… even if that ‘trouble’ is criminal.

2 – Andrew Witty thinks he’s changed Glaxo – he said “…This is a significant step toward resolving difficult, long-standing matters which do not reflect the company that we are today…”

Well Andrew, this deal is in the US – what about the UK?

You’re not quite so happy for the new, improved GlaxoSmithKline to settle claims in the UK are you, now Andrew.

Could it be because you know the UK legal system works in your favour, so you can effectively ignore UK cases… in the UK cases like this are not heard in front of a jury, but in front of a high court judge – and funding is not easy to get. Basically in the UK we have no real chance to take on big business and patients not protected by the MHRA.

He is absolutely correct.

His post prompted me to browse through the archives of the Paxil Protest website, a site created by Rob Robinson, a site that was a minefield of information, a site that GlaxoSmithKline wanted shut down. One does not have to be a highly paid lawyer to see why they wanted it removed.

I've been writing about the MHRA, GlaxoSmithKline and Seroxat for 6 years. If I continued to write for a further 20 years I wouldn't come anywhere near what Robinson achieved. The man is a legend.

The following shows how effective Robinson was. It ends with a quote from Karen Barth-Menzies, yet another hero/heroine of mine. This is especially for Addleshaw Goddard, GlaxoSmithKline's UK law team.


Paxil Addiction



....there have been a number of systematic studies in humans looking at the potential for Paxil for abuse, tolerance and physical dependence. So actually, there is data to date to negate the statement that it has not been systematically studied, because, in fact, it has been.— Sworn testimony of Dr. David WheadonSenior Vice President, GlaxoSmithKline Regulatory Affairs and Product Professional Services (10/19/2000)

DRUG ABUSE AND DEPENDENCE

Controlled Substance Class: Paxil is not a controlled substance. Physical and Psychologic Dependence: Paxil has not been systematically studied in animals or humans for its potential for abuse, tolerance or physical dependence. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for history of drug abuse, and such patients should be observed closely for signs of misuse or abuse of Paxil (e.g., development of tolerance, incrementations of dose, drug-seeking behavior).— Paxil June, 2005 Prescribing Information

Disregard for the moment that perjured testimony, and the studies that were never done (or ever will be): Any man, woman, or child, who has crawled through the "Hell beyond Hells" that is a severe Paxil withdrawal will tell you (assuming they lived) that, yes, he or she was dependent on the drug; a prisoner, if you will, for the simple reason that continuing to take Paxil staved off horrifying, debilitating and protracted withdrawal symptoms.

It is INSANE that I and others have had to stumble into and through this hell ... and then try to figure out how to get out of it basically on our own! Its like being thrown into a chemical version of Dante’s Inferno with no map showing you how to get out — or even if you can get out at all! I think (but don’t hope) I’m close to clawing my way out, but who knows? I hate to say it, but the thought just drifted into my head: All ye who enter here abandon all hope.— Journal entry, day #89 from a Paxil withdrawal diary kept by Rob Robinson, a Paxil survivor.

In the mind of a lay person this inability to quit Paxil qualifies as "addiction" regardless of whether a Paxil user craved the drug to "get high," like a "real" addict craves, for example, heroin.

How GlaxoSmithKline has dealt with the issue of Paxil dependency (i.e. addiction) mirrors efforts it undertook regarding the issue of Paxil withdrawal. GSK flatly denies that Paxil can cause dependency or addiction and, in fact, the company has gone to extraordinary lengths to keep the label of dependency or addiction from being associated with the use of Paxil.

The truth is GSK knows Paxil can, sans studies, cause physical dependency in significant numbers of people. That is absolutely the case. It is one of the principal reasons why GlaxoSmithKline has, for years, instructed its sales reps to, whenever possible, substitute the word "discontinuation" for "withdrawal" in communications with healthcare professionals — because withdrawal implies dependency. And dependency, quite naturally, suggests addiction.

Yet the volume of anecdotal information available to GlaxoSmithKline and the world — proving Paxil can, and does, cause dependency — is widespread, dramatic, compelling and overwhelming.

Charles Medawar, of Social Audit framed the issue perfectly when he wrote:

“There is obviously some confusion about the concept of dependence ... The simplest definition of drug dependence given by W.H.O. (the World Health Organization) is ‘a need for repeated doses of the drug to feel good or to avoid feeling bad’ (W.H.O., Lexicon of alcohol and drug terms, 1994). When the patient needs to take repeated doses of the drug to avoid bad feelings caused by withdrawal reactions, the person is dependent on the drug. Those who have difficulty coming off the drug even with the help of tapered discontinuation should be regarded as dependent, unless a relapse into depression is the reason for their inability to stop the antidepressant medication.”


Thanks to Mr. Medawar’s relentless efforts to expose the truth about Paxil (Seroxat in the U.K.) GlaxoSmithKline was forced to remove from its U.K. Patient Information Leaflet the following language:

“These tablets are not addictive” and “remember that you cannot become addicted to Seroxat,” and further that the withdrawal symptoms some people experience when stopping Seroxat “are not common and (they) are not a sign of addiction.”

Shattering GlaxoSmithKline's DSM IV "No Dependency" Shield

For now forget the studies GlaxoSmithKline refers to in Paxil's prescribing information mentioned above; those studies will never be performed for the simple reason they would provide conclusive evidence that use of Paxil can induce dependency. Evidence which would present an insurmountable threat to the fortunes of GlaxoSmithKline.

Today, the GlaxoSmithKline public act which claims Paxil cannot induce dependency — based on the latest version of the Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (a.k.a. the DSM IV) — would play well if this were the "Theater of the Absurd." But not out here in the real world where lives are being shattered and people are dying because of Paxil.

The GSK dodge seeks refuge under cover of language which changed when the DSM III was supplanted by the DSM IV in which, according to Charles Medawar of Social Audit "the new definition of dependence specified that the presence of withdrawal symptoms — in the absence of at least two distinctive features of a drug problem — was not "dependence" at all. At a stroke therapeutic dependence ... officially ceased to exist. Once again, the problem revolved around the true meaning of "dependence" but, this time, the new definition both radically changed the meaning and defied common sense. To compound the problem the authorities then failed to explain, or even acknowledge, that this enormous shift in meaning had taken place.

The Pharmas zealously promoted the new definition, but the medical establishment welcomed it too — because it characterized "dependence" as something that no competent doctor would ever cause. As if by law, and at a stroke, "dependence" had again come to mean something like frank drug abuse. In line with tradition, dependency problems were pinned on users once again.

Internationally, the risk of New Dependence was considered so small, that the regulators never requested the SSRI Pharmas test their drugs.

For the sake of argument let's have the public give GlaxoSmithKline the benefit of the doubt, even though it's unwarranted. We can "test" GSK's specious DSM IV claim by parsing the manual's criteria for substance dependency on a point-bypoint basis

Remember, only three of the following criteria must be meet within a 12-month period for a diagnosis of substance dependency.

The Diagnostic and Statistic Manual (DSM IV), defines addiction (which it refers to as “substance dependence”) as follows:

A maladaptive* pattern of substance use, leading to clinically significant impairment or distress, as manifested by three (or more) of the following, occurring at any time in the same 12-month period:

(1) Tolerance, as defined by either of the following:

a. A need for markedly increased amounts of the substance to achieve intoxication or desired effect.

Many Paxil users must take larger doses of the drug over time as the efficacy of the drug wears off in order to achieve the desired effect.


b. Markedly diminished effect with continued use of the same amount of the substance.

Many Paxil users experience "SSRI poop out" (see D.J. Rapport, J. R. Calabrese, Tolerance to fluoxetine. J Clin Psychopharmacol 1993 Oct, 13 (5), 361.) after taking a fixed dose of the drug for a number of years. As a result they must increase their dosage in an attempt to regain efficacy. Even then, the increase in dosage sometimes has no effect.


(2) Withdrawal, as manifested by either of the following:

a. The characteristic withdrawal syndrome for the substance.

The phenomenon of Paxil withdrawal is an established fact now, and one acknowledged in the manufacturer's current drug labeling.


b. The same (or a closely related) substance is taken to relieve or avoid withdrawal symptoms.

Individuals trying to quit Paxil sometimes switch to another "SSRI" with a longer half-life (i.e. Prozac) in a attempt to simultaneously get off the drug and ameliorate its oftentimes severe withdrawal symptoms. (Like heroin addicts who use methadone.)


(3) The substance is often taken in larger amounts or over a longer period than was intended (loss of control).

Many individuals continue taking Paxil — long after they would like to stop taking the drug — to stave off extremely severe, debilitating and prolonged withdrawal symptoms that sometimes occur when stopping Paxil.


(4) There is a persistent desire or unsuccessful efforts to cut down or control substance use (loss of control).

"Same comment as for #3." Many individuals continue taking Paxil — long after they would like to stop taking the drug — because of the withdrawal symptoms that occur when stopping Paxil.


(5) A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects (preoccupation).

If Paxil was illegal many users would spend whatever time was necessary to get the drug "on the street," thus engaging in the same behaviors "real" addicts exhibit in their quest to obtain the drug they are dependent upon. A Paxil addict doesn't have to go this route since the doctor who (unwittingly) prescribed Paxil to him or her hands out refill prescriptions; all that's necessary to get more Paxil is a trip to the local pharmacy.


(6) Important social, occupational, or recreational activities are given up or reduced because of substance use (continuation despite adverse consequences)

(7) The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. (adverse consequences)

This is the situation lived out on a daily basis for thousands of Paxil dependents who have (quite often) discovered through the Internet why it is they are unable to quit the drug without experiencing disabling withdrawal symptoms.


Paxil and proof of dependency: In basketball it's what they call "a slam dunk."

In legal documents GlaxoSmithKline appears to make much out of the word "maladaptive" as used in the DSM pre-qualifier. In this context an acceptable medical synonym for the word "maladaptive" is "dysfunctional." If Paxil dependency is not a state of dysfunction (i.e. maladaptation) then the condition doesn't exist.

Based on what the world knows about Paxil today: Paxil should be — if not summarily banned — then at a minimum classified as a "Schedule II" drug by the United States Drug Enforcement Agency. (At the same time the DEA should change its scheduling guidelines under "(C)" to read "use of" vs. "abuse of" since that language lags behind today's realities.)

Rob Robinson - Paxil Protest

"We have been trying for years to raise public awareness about these issues because we have seen, through our litigation, the secret internal company documents that no one ever gets to see, not even the FDA. Even now, we are prohibited, due to confidentiality orders, from disclosing these documents. But, you can only hide the truth for so long. Too many people have been harmed by these drugs, too many lives have been shattered." - Karen Barth-Menzies - Paxil plaintiffs' attorney







Thursday, June 11, 2009

GlaxoSmithKline's David "The Grim Reaper" Wheadon

The following is taken from the archives of Paxil Protest, a site created by former Paxil activist, Rob Robinson. The site was removed, allegedly as part of an out of court settlement deal.

The world owes Rob Robinson a huge debt. His campaigning has no doubt saved thousands of lives and his courage for standing up against a huge corporation will ensure that fellow advocates, such as myself, will have the strength to pursue the truth and stand up for what we believe in.

Rob Robinson deserves an award. His name will forever haunt those responsible for the Seroxat debacle.

This blog salutes you Rob.

----

The following series of exchanges are verbatim excerpts from a transcript of a video deposition taken of Dr. David Wheadon, Vice President Regulatory Affairs and Product Professional Services, GlaxoSmithKline, in Philadelphia, PA on Thursday, October 19, 2000 prior to a civil suit involving a Paxil triple homicide/ suicide (which GSK lost.) Nothing appearing on this page can be claimed (by GSK) as "quoted out of context." Questioning Dr. Wheadon are California attorney Donald J. Farber and Texas attorney Andy Vickery.

During this deposition Dr. Wheadon committed perjury on at least one occasion:

see "Exchange #1" below.

This was a two part deposition; part one can be found by clicking on this link.

Man is the only kind of varmint that sets his own trap, baits it, then steps in it.
John Steinbeck
Sweet Thursday


Wheadon Exchange #1
"There Have Been a Number of Systematic Studies"

Paxil Victim's Attorney: I'm asking you to kind of elevate yourself above this particular paper and go to your general knowledge now on Paxil. You have been now with the company eight years, and you have studied and are aware, I presume, of Paxil's traits in either causing or unrelated to addiction and withdrawal, and based on that general knowledge I think you probably have, do you consider as a labeling instruction today that this paragraph, physical and psychological dependence, is a good labeling instruction?

GlaxoSmithKline's Dr. Wheadon: Well, quite frankly, it is an outdated labeling instruction, because there have been a number of systematic studies in humans looking at the potential for Paxil for abuse, tolerance and physical dependence. So actually, there is data to date to negate the statement that it has not been systematically studied, because, in fact, it has been.

*******************

The June, 2005 Paxil prescribing information (excerpted below) provides readers an opportunity to contrast what today's Paxil prescribing information states in stark contrast to Dr. Wheadon's year 2000 (perjured) testimony.

DRUG ABUSE AND DEPENDENCE
Controlled Substance Class: Paxil is not a controlled substance. Physical and Psychologic Dependence: Paxil has not been systematically studied in animals or humans for its potential for abuse, tolerance or physical dependence. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for history of drug abuse, and such patients should be observed closely for signs of misuse or abuse of PAXIL CR (e.g., development of tolerance, incrementations of dose, drug-seeking behavior). — Paxil June, 2005 Prescribing Information

Wheadon Exchange #2
"Let's Just Wrap This Up and Move On to Something Else, Please."

GlaxoSmithKline's Attorney: Mr. Farber, I'd like you to wrap this area up, because dependence and withdrawal is not the subject matter of the 30(b)(6).

Paxil Victim's Attorney: I understand your concern.

GlaxoSmithKline's Attorney: And I thought we made that clear at the start.

Paxil Victim's Attorney: Well, I connect it. Basically, we are talking now — you know, I have a fraud count in my Complaint. You are aware of that?

GlaxoSmithKline's Attorney: You have told me that, yes.

Paxil Victim's Attorney: Okay, and as part of fraud, allegedly misleading statements on any facet of Paxil to get Paxil approved by the FDA in 1992 is certainly an element of fraud, and it is certainly discoverable information. Whether or not it is a suicide or violence issue is not the issue. The issue is misleading information of any type to get Paxil approved.

GlaxoSmithKline's Attorney: Let's just wrap this up and move on to something else, please.

Paxil Victim's Attorney: Well, I'm going as fast as I can. If your client (Dr. Wheadon) would be just a little more specific — and I'm not saying he shouldn't be evasive, but the more evasive he is, the longer it takes.

Wheadon Exchange #3
"I Do Not Know." "I Have No Idea."

Paxil Victim's Attorney: Do you recall a study — the number is P-A-R, Par — by the way, does that mean Paroxetine?

GlaxoSmithKline's Dr. Wheadon: Yes.

Paxil Victim's Attorney: That's what I thought it meant. On study Par 08-03 conducted in Yugoslavia from late '89 to early '91, do you remember reviewing that study in general?

GlaxoSmithKline's Dr. Wheadon: I think the actual study is Par 08-3, which was a long term depression study done in Yugoslavia.

Paxil Victim's Attorney: By the way, maybe you don't know, but who was the principal investigator in Yugoslavia on that study?

GlaxoSmithKline's Dr. Wheadon: I do not know.

Paxil Victim's Attorney: I'm sure that fact is in the records somewhere at SmithKline, no doubt; correct?

GlaxoSmithKline's Dr. Wheadon: I have no idea.

Paxil Victim's Attorney: You don't have any idea whether you keep records of who principal investigators are?

GlaxoSmithKline's Dr. Wheadon: I said, Mr. Farber, that I have no idea who the investigator in Par 08-3 is or was.

Paxil Victim's Attorney: That wasn't my question. My question was whether the records would reflect that, and you said you had no idea.

GlaxoSmithKline's Dr. Wheadon: I would imagine that records would reflect that, yes.

Paxil Victim's Attorney: That's what I'm talking about. I don't want to be contentious here, but the more evasion we get, the longer it takes.

GlaxoSmithKline's Attorney: He is answering your questions, Mr. Farber, to the best of his ability.

Paxil Victim's Attorney: Well, he didn't. I had to spend an extra two minutes to get an admission here, which I thought was fairly obvious. And just for the record, that's why these things take so long. And I'm going to take as long as I have to, no matter how many days, to get the information. End of speech.

Wheadon Exchange #4
"Regarding a Certain 'Exhibit #14'"

Paxil Victim's Attorney: But I'm going back to the word discontinuation. If you said to the board, on their voting day, that you had an attempt in Par 08-3 to systematically assess a discontinuance syndrome, why would your instructions issued two months later state to the contrary, that there was no attempt to systematically observe the discontinuation syndrome?

GlaxoSmithKline's Dr. Wheadon: I can only speak to the document that you have put in front of me, which I can identify, and the statement is that this was our attempt to systematically assess a discontinuation syndrome, meaning using the Par 08-3 data. I cannot speak to what you keep going back to, that being Exhibit 14, which I have no ability to identify or to verify.

Paxil Victim's Attorney: Well, I will take the time. Maybe we can get this later at some point, but I do want the contradiction explained at some point. I understand what you are saying now. But if what I put before you is true, on Exhibit 14, if that's true, can you explain the obvious discrepancy between the systematic and the nonsystematic words in these two documents?

GlaxoSmithKline's Dr. Wheadon: I cannot at this time, no.

Wheadon Exchange #5
"It Has To Do With Fraud Getting This Approved."

Paxil Victim's Attorney: Now, on the issue of relapse, unquote, versus withdrawal or discontinuation syndrome, do you recall, at the October 5th meeting, that the issue of relapse criteria that had been established for Par 08-3 back in '88 or when the protocol was written, do you recall what the relapse — in general, I'm not asking you to quote it, but do you recall what the relapse criteria was?

GlaxoSmithKline's Dr. Wheadon: I do not recall exactly what that criteria was.

Paxil Victim's Attorney: Do you remember the subject, though, of the relapse criteria, whether it was too stringent or about right? Do you recall the criteria standard being discussed at the committee meeting during discussions?

GlaxoSmithKline's Dr. Wheadon: Quite frankly, I do not recall.

Paxil Victim's Attorney: Now, I'm going to ask you a more general question based on your professional background. On the general issue of relapse and withdrawal, I don't know if this is true. Would you tell me if it is true that if a person, a patient, who has been taking Paxil — and can we define basically the withdrawal conditions as either being — and I think I have quoted this from your publications — either being a taper, a gradual tapering down of Paxil use or an abrupt quitting of Paxil altogether, so a reduction of Paxil use by a patient. When that occurs, and two days later, let's assume, the patient was taking Paxil regularly for three months under my hypo. Two days later, after abruptly quitting, the patient then suffers symptoms. Now, my question is concerning symptoms. Would you agree that the symptoms upon review by the physician, that it might be an open question whether the patient were then suffering withdrawal or was suffering a relapse into his prior depressive state? In other words, is that a difficult situation or is it an important situation to assess correctly from the physician's point of view?

GlaxoSmithKline's Attorney: Mr. Farber, what does this have to do with the Lacuzong case?

Paxil Victim's Attorney: It goes back to the issue of approval. If we could — I want to go off the record.

GlaxoSmithKline's Attorney: I don't want to go off the record.

Paxil Victim's Attorney: Okay. It has to do with fraud getting this approved.

GlaxoSmithKline's Attorney: Mr. Farber, the subject matter of today's deposition was defined in the 30(b)(6), which, for whatever reason, you apparently have not read, and you are entitled to ask any questions you want within that subject matter as it relates to the Lacuzong case, which has nothing to do with withdrawal at all. So I think you are going to have an opportunity to deal with that in another context. The witness hasn't been prepared on this. And I want to use the time fruitfully for you inasmuch as the 30(b)(6) defines the scope of this deposition, and we are going to argue that you get no more questioning in any of the areas in the 30(b)(6), so I would like to make the best use of this time in covering that, because you will have ample time to deal with your withdrawal case, which has nothing to do with Lacuzong.

Paxil Victim's Attorney: I appreciate that, counsel. I agree with what you just said, but I'm talking now about Doctor Wheadon's own presentation before this committee in October of 1992 to get this drug approved.

GlaxoSmithKline's Attorney: But that wasn't your last question.

Paxil Victim's Attorney: That is the general line of query here. I'm only dealing with his representations and why he said what he said at that committee hearing to get this drug approved. That's very important. Now, if you want to go on the record now and say we will discuss that entire subject at a later deposition in San Jose or anywhere, that's fine with me. I will take your commitment there. But whether it is Doctor Wheadon or not, I'm discussing his testimony now before this committee.

GlaxoSmithKline's Attorney: Ask your question as it relates to his appearance at the hearing then.

Paxil Victim's Attorney: On the issue of relapse, was the standard of relapse discussed at that hearing in your exchanges with committee hearing? Do you remember that?

GlaxoSmithKline's Dr. Wheadon: As I stated earlier, Mr. Farber, I do not recall a discussion concerning the definition of relapse in the Par 08-3 data.

Paxil Victim's Attorney: Okay, I'm done with that subject. Now, let's get into suicide.

Wheadon Exchange #6
"70 Percent of the Scripts are Written by Non-Psychiatrists"

Paxil Victim's Attorney: Now, I take it that one of the things that made you attractive to SmithKline Beecham, when you were recruited in '92, was that you had considerable experience at Lilly in working on Prozac, and particularly, at the time of the launch; is that true?

GlaxoSmithKline's Dr. Wheadon: I have no idea what made me attractive to SmithKline Beecham.

Paxil Victim's Attorney: You mean, in the interview process, they didn't seem excited about the fact that you had that experience?

GlaxoSmithKline's Dr. Wheadon: Well, certainly, they were interested in my experience as a psychiatrist, and certainly, my experience at Lilly was a part of that. But again, I can't say what made me particularly attractive to them.

Paxil Victim's Attorney: Well, your experience as a psychiatrist in terms of practicing was as a psychiatrist in the context of working for a big pharmaceutical company, rather than a psychiatrist in a private clinical practice; isn't that true?

GlaxoSmithKline's Dr. Wheadon: Additionally having been trained as a psychiatrist, yes.

Paxil Victim's Attorney: Incidentally, having been trained as a psychiatrist, what do you think about the fact that 70 percent of your company's market for Paxil is people who did not have that kind of training?

GlaxoSmithKline's Dr. Wheadon: I'm not sure what you are asking.

Paxil Victim's Attorney: Do you endorse the idea of non-mental health care professionals diagnosing depression and treating it with psychoactive drugs like Paxil?

GlaxoSmithKline's Dr. Wheadon: Yes, I do.

Paxil Victim's Attorney: And isn't that about 70 percent of Paxil's market, nonmental health care professionals?

GlaxoSmithKline's Dr. Wheadon: If I recall correctly, 70 percent of the scripts are written by non-psychiatrists.

Wheadon Exchange #7
"This Whole Suicide Issue is Just a PR Problem, Don't Worry About It."

Paxil Victim's Attorney: I got seven minutes here. I will finish one way or the other. New subject, suicide and the suicide issue in total, what Mr. Vickery was talking about and this whole issue of Prozac and so forth, is that a public relations problem for your company? Do you consider that — I know it doesn't have a precise answer. I'm just asking for your opinion. Does this present a public relations problem for SmithKline Beecham?

GlaxoSmithKline's Dr. Wheadon: Frankly, it presents a problem for the psychiatric field and for the cause of insuring that people are willing to seek mental health care. One of the issues in this country has always been that there is a closeted notion about people with psychiatric illness. And this serves a great disservice to people that really need to be willing to come forward and get care. So from that standpoint, SmithKline and I, as a psychiatrist, are very concerned about this issue.

Paxil Victim's Attorney: I agree with that. I totally agree with that. And my question is, if, therefore, it were deemed to be studied as an issue, as a valid scientific inquiry, is it not proper for the authorities, such as FDA and SmithKline, to, in fact, treat it as a clinical serious problem for studying, rather than themselves treating it as a PR problem? Do you agree with that proposition?

GlaxoSmithKline's Dr. Wheadon: I don't understand your question.

Paxil Victim's Attorney: Well, if it is a serious problem, and I agree, it is a very serious problem, and it were deemed to be important enough to be held at an FDA hearing to determine that, isn't it an important enough subject to be studied scientifically?

GlaxoSmithKline's Dr. Wheadon: And it has been studied scientifically.

Paxil Victim's Attorney: Are you aware that Doctor Brecher called SmithKline — I know this happened before your watch, and if you don't know anything about it, you can tell me, but are you aware or did somebody tell you that Doctor Brecher called SmithKline on October 3rd, 1990, and basically said, this whole suicide issue is just a PR problem, don't worry about it? That's my words.

GlaxoSmithKline's Dr. Wheadon: I'm not aware of that.

Paxil Victim's Attorney: Let's go to Exhibit 18.

Whereupon the court reporter marked document as Exhibit 18 for identification.
*******************

GlaxoSmithKline's Attorney: Mr. Farber, whose writing is this on the margin?

Paxil Victim's Attorney: Preconceived?

GlaxoSmithKline's Attorney: Right, and PR.

Paxil Victim's Attorney: It is my writing. I will specify that for the record.

GlaxoSmithKline's Attorney: I would like a copy that goes in that is free of this for the exhibit.

Paxil Victim's Attorney: That's fine. I have no problem with that. We will get a corrected copy for the thing, okay? So the original exhibit will have this deleted. Now, this general subject reported in the summary of conversation — I know you weren't there at the time, and you may not have seen this, but are you aware of this general subject that an FDA official called SmithKline at some point before your arrival and indicated that the suicide issue was merely a PR problem?

GlaxoSmithKline's Dr. Wheadon: No, I was not aware.

Paxil Victim's Attorney: Exhibit 19, same thing, if you don't like my funny face, I will delete that. There is a funny face on this.

GlaxoSmithKline's Attorney: I think we should delete it.

Paxil Victim's Attorney: We will. I have no problem deleting it.

Whereupon the court reporter marked document as Exhibit 19 for identification.
*******************

Paxil Victim's Attorney: Exhibit 19 is a FDA conversation record, July 19th, from a conversation with Tom Laughren, M.D., at FDA, calling Thomas Donnelly, the regulatory affairs officer. And basically, I will summarize. I don't think you will have a problem with this. There is a call, where Doctor Laughren called SmithKline and wanted assistance for a ten-year data base and asked the company for a large data base, so he could go out and give a presentation on it personally, out of official business. That's what this says. That's my summary. And my question to you is this: Is it standard operating procedure at SmithKline to do personal favors for FDA officials?

GlaxoSmithKline's Dr. Wheadon: No.

Paxil Victim's Attorney: Has SmithKline under your watch, at least as far as you know, ever met socially with — let me go back. In 1992, from the time you arrived in February, up until the committee meeting in October of '92, did any SmithKline official have contact with any of the six members who sat on that committee meeting on October 5th?

GlaxoSmithKline's Dr. Wheadon: That is such a broad question, Mr. Farber, I quite frankly have no ability to answer that.

Paxil Victim's Attorney: No, if you don't know, I would understand that. But you don't know; correct?

GlaxoSmithKline's Dr. Wheadon: I have no idea.

Paxil Victim's Attorney: Would it be contrary to company policy to make personal contact with any committee member who was assigned to sit on an impending committee to consider a SmithKline product in the approval process?

GlaxoSmithKline's Dr. Wheadon: You have to be far more specific. It would not be unusual for a scientist and a member of an FDA committee to be present at the same meeting. They may have a conversation on the scientific issue that may be discussed at that meeting. So simply having contact, meaning running into one another at a meeting and having a friendly discussion is certainly not outside of company policy, no.

Paxil Victim's Attorney: I'm not talking about the day of the meeting. Let's eliminate the day of the meeting and coffee breaks and all that nature. I'm talking about the lead-up to the meeting, when the members have been identified, and a drug of your company will be under consideration by that committee. Is there a company policy preventing, call it a conflict of interest policy or whatever you want to call it, such a policy in effect to preclude social or any personal contacts with any of the committee members?

GlaxoSmithKline's Dr. Wheadon: I answered previously, and I think you may have misunderstood my answer, it is not outside the realm of possibility, and it is perfectly acceptable if a member of the company and a member of an advisory committee happened to run into one another at a scientific meeting, not the advisory committee meeting, and exchanged pleasantries and maybe have a brief discussion, that is acceptable.

Paxil Victim's Attorney: How about a concentrated attempt to contact one of these officials specifically for the purpose of discussing the issue?

GlaxoSmithKline's Dr. Wheadon: That is contrary to company policy.

Paxil Victim's Attorney: I'm not done, but I will quit here in one minute.

Whereupon the court reporter marked document as Exhibit 20 for identification.
*******************

Paxil Victim's Attorney: I guess I'm cut off here. Just for the record, I'm not done, counsel, but for today, I will quit here in one minute. My Exhibit Number 20 is a memorandum and a fax, really, from Doctor Laughren to Tom Donnelly, and you will see it is dated August 25, 1992, after your arrival at SmithKline, and it is a twopage letter, and he talks — I'm specifically focusing on Page 2. My question concerns Page 2 in the second paragraph under discontinuation for adverse events. And you can see it is a dialogue. I will read it. It says, quote, I find that a number of events occurring at an incidence of 1 percent or greater for Paroxetine in Appendix 4-B are not in this section; e.g., vomiting, confusion, manic reaction, abdominal pain, hypertension, palpitation, paresthesia, constipation, decreased appetite, weight gain, CNS stimulation. This discovery erodes my confidence somewhat, and I would like an explanation for this fairly obvious discrepancy, unquote. Does this general subject ring a bell with you as to what Mr. Laughren was talking about, Doctor Laughren was talking about?

GlaxoSmithKline's Dr. Wheadon: I'm quite frankly not familiar with this particular item, nor this particular topic.

Paxil Victim's Attorney: So nothing that I have just read rings a bell at all?

GlaxoSmithKline's Dr. Wheadon: No.


Copyright Paxil Protest

Paxil Protest Disclaimer of Liability
The user assumes all responsibility and risk for the use of this website and the Internet generally. Under no circumstances, including negligence, shall anyone involved in creating or maintaining this website, or shall the website owners or any of their directors, officers, employees or agents be liable for any direct, indirect, incidental, special or consequential damages, or lost profits that result from the use or inability to use the website and/or any other websites which are linked to this site.

Nor shall they be liable for any such damages including, but not limited to, reliance by a member or visitor on any information obtained via the website; or that result from mistakes, omissions, interruptions, deletion of files, viruses, errors, defects, or any failure of performance, communications failure, theft, destruction or unauthorized access.

All content on this website is provided to you on an “as is” and “as available” basis without warranty of any kind, either express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, and noninfringement.

Paxil Protest makes no warranty as to the accuracy, completeness, currency, or reliability of any content available through this website.

In states which do not allow some or all of the above limitations of liability, liability shall be limited to the greatest extent allowed by law.

Any information on this website may be removed without notice. Information may include technical inaccuracies or typographical errors. Furthermore, information posted at this website may change from time to time without notice.

Fair Use Notice
This may contain copyrighted (©) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.


----

SEROXAT SUFFERERS STAND UP AND BE COUNTED

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Friday, June 05, 2009

Nasty effects as patients quit drug

Source: New Zealand Herald


4:00AM Saturday Jun 06, 2009
By Martin Johnston

Patients taking a common anti-depressant have told of considering taking their own lives and experiencing other nasty side-effects when trying to quit the drug.

Nine people contacted the Weekend Herald to relate bad experiences of anti-depressants, after an article last week about Jude Pinkerton and the reactions she suffered.

The 22-year-old spoke out about paroxetine hydrochloride after she descended into a mental "fog" and twice tried to commit suicide before being taken off the drug in April.

She said she was recovering, but still believed she was suffering its ill-effects.

Three who emailed the Weekend Herald complained of serious problems when quitting paroxetine.

One, who asked not to be named, said she had been unable to stop taking the drug - she started in 2004 - because when she tried to quit, the side-effects were so bad.

"Even by reducing dosage very slowly over many months I eventually reached a point of having extremely severe withdrawal symptoms including suicidal feelings, akathisia [restlessness], shaking, vomiting and inability to sleep or eat. I have basically become a drug addict.

"The medical and pharmaceutical community cover up this withdrawal syndrome by labelling it 'return of original symptoms'."

"I now wish I had never started taking this dangerous chemical."

The "withdrawal syndrome" of paroxetine is well known to psychiatrists, but they disagree on how big a problem it is.

"Paroxetine withdrawal is a major problem," said psychiatrist Associate Professor David Menkes, of Auckland University and Waikato Hospital.

But his university colleague Dr Simon Hatcher said it was an issue, but not a big one.

Data for the Aropax brand of paroxetine says trials found withdrawal problems occurred in 30 per cent of adults on the drug, compared with 20 per cent on placebo pills.

Symptoms included dizziness and confusion - and, in young people, who are allowed the drug only under strict conditions, suicide attempts. Some studies have linked anti-depressants to an increased risk of suicidal thoughts and attempts, but state drugs regulator Medsafe says "suicidality ... has not been proven to correlate with or lead to completed suicide".

Professor Menkes said the paroxetine/fluoxetine group were less effective and more prone to bad reactions than most prescribers realised. But they also worked well for some and had saved lives.

Dr Hatcher said it was important doctors explained the possibility of withdrawal problems.

Related links:
Depression pill linked to suicide bids

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

GlaxoSmithKline Exposed Part II

Following on from 'GlaxoSmithKline Exposed Part I', here comes the second installment from former Paxil activist, Rob Robinson's brilliant, groundbreaking website, Paxil Protest [now removed]

Everyone has a right to see what Rob wrote – hence the re-publishing of it on Seroxat Sufferers.



Garnier Comes Out Fighting

In this June 6th, 2004 interview with Sylvia Pfeifer and Robert Peston of the Telegraph, GSK's chief executive tells why the lawsuit filed by the New York attorney general has "made him very angry."

Jean-Pierre Garnier knows all about having to defend his reputation. The 57-yearold chief executive of GlaxoSmithKline, Europe's largest pharmaceutical group, has spent much time over the past year fending off accusations of being an excessively remunerated "fat cat."

But today Garnier and GSK face a more serious charge, having been accused of indulging in "repeated and persistent fraud" by concealing information about the company's best-selling product, the antidepressant Paxil.

In a lawsuit filed on Wednesday, Eliot Spitzer, the attorney-general of New York state, claims that GSK withheld information from doctors about the negative results of clinical trials it conducted into the use by children of Paxil.

Spitzer wants GSK to be fined the profits it made from under-18s using Paxil, a group he estimates accounted for sales of $55m (£30m) in the US in 2002. Were GSK to lose the case, analysts estimate the fine could amount to $150m – not much compared with GSK's earnings last year of £4.5bn.

Reputationally, however, the lawsuit carries much greater risk, something that Spitzer's previous targets, including some of Wall Street's finest investment banks, are acutely aware of.

And with big pharma already in the firing line for its supposedly expensive medicines ahead of this autumn's election in the US, the stage is set for battle.

Characteristically, Garnier has come out fighting. He vigorously defends GSK's record and reveals that the company had no advance warning the lawsuit was coming.

"I think this is very unfortunate because our reputation is attacked and we are not getting a fair chance to rebut because this is the almighty District Attorney office from mid-Manhattan. This is a heavyweight and I hope our voice will be heard and I hope people will not judge us on this press release from Mr Spitzer's office. It's unfair," he says.

The lawsuit alleges that GSK published and disseminated only one of five studies it conducted on the impact of the drug on children, and suppressed the negative results of the other studies "which failed to demonstrate that Paxil is effective and which suggested a possible increased risk of suicidal thinking and acts", according to Spitzer. GSK is also alleged to have failed to disclose this information in "Medical Information Letters" sent to physicians.

Is there anything GSK could have done differently? No, says Garnier, noting that people may have become confused about testing procedures. He says that results of trials to test the safety of potential new medicines are notified immediately to the Food and Drug Administration, the US regulator, if new "indications" are found. To test efficacy, companies have a series of studies done and only when all the conclusions are in are they presented to the regulator. "Our bad luck, in a way, is that the first study came in positive and we informed medical congresses because there was a lot of interest in it. The subsequent studies were negative, so once we had all the studies we told the FDA," says Garnier.

Did GSK do everything perfectly? "I'm not sure," Garnier concedes, "but you know, overall the pattern is very clear, that we did what we were supposed to do . . . Mr Spitzer makes the case that we advertised the positive studies more. That is absolutely incorrect. What happens is that if there is a positive effect, that's news. When there is a negative effect, there is no news."

But how does he explain an internal memo from 1998, first published in Britain last year, which says that GSK intended "to manage the dissemination of [the] data in order to minimise any potential negative commercial impact"?

"Here's an interesting case in point," Garnier says. "Can a company control the millions, and I mean millions, of memoranda written by, in our case, 110,000 people? What are the odds that stupid memos were written? What are the odds that memos asking the company to do things against company policy will be written? The odds are 100 percent!

"Of course we didn't follow this advice. Of course we didn't selectively publicise the data. This is not a smoking gun. It's a stupid memo and there are lots of stupid memos in every company's file and it is really unfair to look at the company's action through the small hole of one memo written among thousands and thousands in 1998. I do regret that those memos exist but I'm not going to lose sleep over the fact."

Garnier is adamant too that commercially it would simply have made no sense to break the rules. "Some people say this is a commercial pressure. This is 3 per cent of the depression market. Do you think you are going to put your reputation at stake to gain something there?" he thunders.

So what happens next? Analysts are not ruling out other states jumping on the bandwagon, nor the possibility of class action lawsuits being filed in the US. So far, says Garnier, there are no signs of that but the industry as a whole is becoming too easy a target.

"It's becoming too easy for many people to attack the pharma industry and hold the pharma industry to standards that are higher than anywhere else. I don't have a problem with the standards but I do have a problem with extortion."


In the latter part of August, 2005 GlaxoSmithKline paid a $2.5 million dollar fine to the state of New York and further agreed to set up a Internet-based clinical trials registry — thus avoiding trial. However, according to Mr. Spitzer, GSK and J.P. Garnier, its chief executive, appeared unrepentant with regard to changing behaviour over disclosure of adverse clinical data. He warned that GSK was still being watched, as were all other pharmaceuticals companies. “The arrogance of the (GSK) commentary is offensive and problematic,” Spitzer said. “We are going to be watching them with a hawk’s eye to see that they have abided by the terms of the settlement.” Spitzer went on to say GSK’s comments following the settlement characterized the settlement as another legal annoyance, and showed too little contrition for the substantive evidence he had against it.

In the end, however, Mr. Spitzer's lawsuit turned out to be the least of GlaxoSmithKline's legal concerns. On April 12, 2005, a shareholders' class actionsuit was filed against GSK on behalf of company stockholders. In an interesting twist, Mr. Garnier was named as a defendant. Here follows a large excerpt from that lawsuit.

More Than Just 'One Stupid Memo'
Garnier acted as a controlling person of GlaxoSmithKline (within the meaning of §20(a) of the 1934 Act). By virtue of his high-level position, participation in and/or awareness of GSK’s operations and/or intimate knowledge of its internal financial condition and business practices, Garnier had the power to influence and control and did influence and control, directly or indirectly, the decision-making of GlaxoSmithKline, including the content and dissemination of the various statements which GlaxoSmithKline contends are false and misleading.

GlaxoSmithKline controlled Garnier and all of its employees. Garnier was provided with or had unlimited access to copies of GlaxoSmithKline’s internal studies, reports, press releases, public filings and other statements alleged by GlaxoSmithKline to be misleading prior to and/or shortly after these statements were issued and had the ability to prevent the issuance of the statements or cause the statements to be corrected.

In particular, Garnier had direct involvement in or intimate knowledge of the day-today operations of GlaxoSmithKline and therefore is presumed to have had the power to control or influence the particular transactions giving rise to the securities violations as alleged herein, and exercised the same.

We missed something big —
we missed the fact that the public wasn't going to necessarily trust us.
— Jean-Pierre Garnier
CEO of GlaxoSmithKline
(8/13/2005)


The fact is GlaxoSmithKline selectively released only data from favorable studies regarding Paxil and concealed data from unfavorable studies, using its employees, paid consultants, and unwitting researchers as conduits to disseminate the misleading information from these studies to the public and investors, as follows:

On 5/30/98-6/4/98, Drs. M.B. Keller, N.D. Ryan and B. Birmaher, et al., presented a poster at the American Psychiatric Association (“APA”) Annual Meeting in Toronto, Canada, entitled “Efficacy of {Paxil} in adolescent depression.” This poster found Paxil efficacious in children and adolescents.

In 98, Drs. K.D. Wagner, B. Birmaher and G. Carlson, et al., presented a poster at the New Clinical Drug Evaluation Unit (“NCDEU”) Annual Meeting in Boca Raton, Florida, entitled “Safety of [Paxil] and imipramine in the treatment of adolescent depression.” This poster found Paxil efficacious in children and adolescents.

In 10/98, Drs. R. Berard and N. Ryan presented a poster at the European College of Neuropsychopharmacology Annual Meeting in Paris, France, entitled “Adolescent depression: Efficacy of [Paxil].” This poster found Paxil efficacious in children and adolescents.

In 8/99, Dr. C. Gagiano presented a poster at the World Congress of Psychiatry Meeting in Hamburg, Germany, entitled “[Paxil] in adolescent depression.” This poster found Paxil efficacious in children and adolescents.

In 12/99, Drs. G.J. Emslie, K.D. Wagner and M.A. Riddle, et al., presented a poster at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting in Acapulco, Mexico, entitled “Efficacy and safety of [Paxil] in the treatment of children and adolescents with OCD [obsessive compulsive disorder].” This poster found Paxil efficacious in children and adolescents.
In 12/99, Dr. Karen Wagner, one of the authors listed on the published article concerning GSK’s study to assess the safety and efficacy of Paxil in treating children and adolescents, Study 329, spoke at a meeting of GSK Neuroscience consultants, at which she discussed Study 329. She was quoted by an internal GSK newsletter as having said: “We can say that [Paxil] has both efficacy and safety data for treating depression in adolescents.”

On 5/13/00-18/00, Drs. B. Birmaher, J.P. McCafferty and K.M. Bellew, et al., presented a poster at the APA Annual Meeting in Chicago, Illinois, entitled “Comorbid ADHD and disruptive behavior disorders as predictors of response in adolescents treated for major depression.” This poster found Paxil efficacious in children and adolescents.

On 5/30/00-6/2/00, Drs. K.D. Wagner, G.J. Emslie and B. Birmaher, et al., presented a poster at the NCDEU in Boca Raton, Florida, entitled “Safety of [Paxil] in the treatment of children and adolescents with OCD.” This poster found Paxil efficacious in children and adolescents.

On 5/5/01-5/10/01, Drs. D.A. Geller, J. Biederman and D.J. Carpenter, et al., presented a poster at the APA Annual Meeting in New Orleans, Louisiana, entitled “Comorbid psychiatric illness and response to treatment in pediatric OCD.” This poster found Paxil efficacious in children and adolescents.

On 5/28/01-31/01, Drs. D.A. Geller, J. Biederman and K.D. Wagner, et al. presented a poster at the NCDEU Annual Meeting in Phoenix, Arizona, entitled “Comorbid psychiatric illness and response to treatment, relapse rates, and behavioral adverse event incidence in pediatric OCD.” This poster found Paxil efficacious in children and adolescents.

GlaxoSmithKline commissioned Drs. M.B. Keller, N.D. Ryan and M. Strober, et al., to write an article about one of GSK’s successful Paxil studies. It was published in an article in the Journal of the American Academy of Child and Adolescent Psychiatry, entitled “Efficacy of [Paxil] in the treatment of adolescent major depression: A randomized, controlled trial.” This article found Paxil efficacious in children and adolescents.

In 11/01, GlaxoSmithKline issued a Medical Information Letter regarding the use of Paxil to treat major depressive disorder (“MDD”) in children and adolescents, which reported studies with positive efficacy results. GlaxoSmithKline also enclosed a published article regarding its favorable study with the Medical Information Letter.

On 5/19-23/02, Drs. D. Gallagher, C. Gardiner and D.J. Carpenter presented a poster at the APA Annual Meeting in Philadelphia, Pennsylvania, entitled “Interim Results: Long-term safety of [Paxil] in pediatric patients.” This poster found Paxil efficacious in children and adolescents.

In 6/02, Drs. D.A. Geller, K.D. Wagner and G.J. Emslie, et al., presented a poster at the NCDEU Annual Meeting in Boca Raton, Florida, entitled “Efficacy of [Paxil] in pediatric OCD: Results of a multicenter study.” This poster found Paxil efficacious in children and adolescents.

In 6/02, Drs. K.D. Wagner, E. Wetherhold and D.J. Carpenter, et al., presented a poster at the NCDEU Annual Meeting in Boca Raton, Florida, entitled “Safety and tolerability of [Paxil] in children and adolescents: Pooled results from four multicenter, placebo-controlled trials.” This poster found Paxil efficacious in children and adolescents.

On 10/11-27/02, Drs. D.A. Geller, K.D. Wagner and G.J. Emslie, et al., presented a poster at the American Academy of Children in Adolescent Psychiatry Annual Meeting in San Francisco, California, entitled “Efficacy of [Paxil] in pediatric OCD: Results of a multicenter study.” At that same meeting, Drs. K.D. Wagner, M.B. Stein and R. Berard, et al., presented a poster entitled “Efficacy of [Paxil] in childhood and adolescent social anxiety disorder.” Also at that meeting, Drs. K.D. Wagner, E. Wetherhold and D.J. Carpenter, et al., submitted an abstract entitled “Safety and tolerability of [Paxil] in children and adolescents: Pooled results from five multicenter, placebo-controlled trials.” These posters and abstract found Paxil efficacious in children and adolescents.

In 12/02, Drs. K.D. Wagner, E. Wetherhold and D.J. Carpenter, et al., published an article in the Journal of Child and Adolescent Psychopharmacology, entitled “Safety and tolerability of [Paxil] in children and adolescents: Pooled results from four multicenter, placebo-controlled trials.” This article found Paxil efficacious in children and adolescents.

In 12/02, Drs. D.A. Geller, K.D. Wagner, and G.J. Emslie published an article in the Journal of Child and Adolescent Psychopharmacology, entitled “Efficacy and safety of [Paxil] in pediatric OCD: Results of a double-blind, placebo-controlled trial.” This article found Paxil efficacious in children and adolescents.

On 12/8/02-12/12/02, Drs. K.D. Wagner, M.B. Stein and R. Berard, et al., presented a poster at the ACNP Annual Meeting in San Juan, Puerto Rico, entitled “Efficacy of [Paxil] in childhood and adolescent social anxiety disorder.” This poster found Paxil efficacious in children and adolescents.

In 1/03, Drs. A. Braconnier, R. Le Coent and D. Cohen published an article in the Journal of the American Academy of Child and Adolescent Psychiatry, entitled “[Paxil] versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial.” This article found Paxil efficacious in children and adolescents.

On 5/17-22/03, Drs. K.D. Wagner, E. Wetherhold and M. Gee, et al., presented a poster at the APA Annual Meeting in San Francisco, California, entitled “Remission of pediatric social anxiety disorder with [Paxil].” This poster found Paxil efficacious in children and adolescents.

On 5/17-22/03, Drs. R. Berard, K.D. Wagner, and D.J. Carpenter, et al., presented a poster at the APA Annual Meeting in San Francisco, California, entitled “SSRI therapy of pediatric patients with social anxiety disorder or OCD.” This poster found Paxil efficacious in children and adolescents.

In 5/03, Drs. K.D. Wagner, E. Wetherhold and M. Gee, et al. presented a poster at the NCDEU in Boca Raton, Florida, entitled “Remission of pediatric social anxiety disorder with [Paxil].” This poster found Paxil efficacious in children and adolescents.

On 6/10/03, a British agency stated that the risk of self-harm and potentially suicidal behavior of youngsters with depression was between 1.5 and 3.2 times greater when treated with Paxil than with a placebo. A British Committee on Safety of Medicines advised that Paxil “should not be used in children and adolescents under the age of 18 years to treat depressive illness.”

On 6/11/03, GlaxoSmithKline issued a statement that “not a single person committed suicide” in the study of children taking Paxil. “We don’t believe there’s any compelling evidence that Paxil causes suicide. If anything, it reduces suicidal tendencies” in patients suffering from depression. This was false because it failed to disclose a number of suicide attempts in children taking Paxil.

On 6/19/03, the FDA issued a Talk Paper in which it stated that it was reviewing data from studies of Paxil use in children and adolescents and, although the review of the safety data was not complete, “FDA is recommending that Paxil not be used in children and adolescents for the treatment of MDD.”

On 6/19/03, GlaxoSmithKline issued a press release which stated that “[i]n the company’s pediatric trials, which included more than 1000 patients treated with Paxil, not a single person committed suicide.” This was misleading because it failed to disclose suicide attempts.

On 6/2/04, the Attorney General for the State of New York sued GlaxoSmithKline based upon GSK’s suppression of adverse studies relevant to Paxil use to treat children and adolescents.

On 8/5/04, The Wall Street Journal published an article which reported that a new analysis by the FDA had confirmed the link between SSRIs and suicidal tendencies in young people.

Copyright Paxil Protest

Paxil Protest Disclaimer of Liability
The user assumes all responsibility and risk for the use of this website and the Internet generally. Under no circumstances, including negligence, shall anyone involved in creating or maintaining this website, or shall the website owners or any of their directors, officers, employees or agents be liable for any direct, indirect, incidental, special or consequential damages, or lost profits that result from the use or inability to use the website and/or any other websites which are linked to this site.

Nor shall they be liable for any such damages including, but not limited to, reliance by a member or visitor on any information obtained via the website; or that result from mistakes, omissions, interruptions, deletion of files, viruses, errors, defects, or any failure of performance, communications failure, theft, destruction or unauthorized access.

All content on this website is provided to you on an “as is” and “as available” basis without warranty of any kind, either express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, and noninfringement.

Paxil Protest makes no warranty as to the accuracy, completeness, currency, or reliability of any content available through this website.

In states which do not allow some or all of the above limitations of liability, liability shall be limited to the greatest extent allowed by law.

Any information on this website may be removed without notice. Information may include technical inaccuracies or typographical errors. Furthermore, information posted at this website may change from time to time without notice.

Fair Use Notice
This may contain copyrighted (©) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.


----

SEROXAT SUFFERERS STAND UP AND BE COUNTED

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Thursday, June 04, 2009

GlaxoSmithKline Exposed Part I



GlaxoSmithKline


Exposed



Taken from the excellent Paxil Protest website archives.


Look past GlaxoSmithKline's public relations facade and what you'll find an unethical corporation whose principal reason for existence is to rake in huge profits for its stockholders.

In fact, one could argue — based on an abundance of evidence accessible to anyone with an Internet connection — that GlaxoSmithKline views the public as little more than its own personal "ATM machine," and whose citizens are apparently suitable for use as experimental animals.



We are a high-integrity company.
We know what the rules are
and we follow them
.
Jean-Pierre Garnier
CEO of GlaxoSmithKline
(6/6/2004)


Integrity? Standards? Surely Mr. Garnier was being facetious. After all, GlaxoSmithKline's way of doing business includes:

Defrauding the public on multiple occasions, and on a massive scale.

Operating in a manner one would commonly associate with an ongoing criminal enterprise.

Engaging in an ongoing pattern of false advertising; here's just one example.

Repeatedly refusing to comply with minimum drug manufacturing quality control standards mandated by the United States Food and Drug Administration that, in 2005, resulted in two GlaxoSmithKline production facilities being shut down and millions of PaxilCR tablets seized by U.S. Federal Marshals.

Trashing the environment in spite of what Dr. Anne Phillips, Vice President, Research & Development and Chief Medical Officer of GlaxoSmithKline has claimed: While GlaxoSmithKline strives to produce medications that safely and effectively treat medical conditions, we're also committed to protecting the environment.

Little wonder GlaxoSmithKline was named one of the ten worst corporations of 2004 by Multinational Monitor. (It's not GlaxoSmithKline's first time on the list either.)

Anatomy of a Paxil Fraud

On June 2nd, 2004 State Attorney General Eliot Spitzer announced a lawsuit against GlaxoSmithKline for concealing important information about the safety and efficacy of Paxil.

The lawsuit alleged that GlaxoSmithKline engaged in repeated and persistent fraud by concealing and failing to disclose to physicians information about Paxil. The lawsuit alleged that, starting in 1998, GlaxoSmithKline engaged in a concerted effort to withhold negative information concerning Paxil and misrepresented data concerning Paxil's safety and efficacy when prescribed for depression in children and adolescents.

Specifically, GlaxoSmithKline conducted at least five studies on the use of Paxil in children and adolescents. However, GSK only published and disseminated one of these studies, which showed mixed results on efficacy. The lawsuit alleged that the company suppressed the negative results of the other studies, which failed to demonstrate that Paxil is effective and which suggested a possible increased risk of suicidal thinking and acts. GSK is also alleged to have failed to disclose this information in "Medical Information Letters" that it sent to physicians.

An internal GlaxoSmithKline document from 1998 shows that GlaxoSmithKline intended to "manage the dissemination of (the) data in order to minimize any potential negative commercial impact."

Spitzer's lawsuit also alleged that GlaxoSmithKline misrepresented the results of its research on Paxil as a treatment for children and adolescents to its sales representatives who promote Paxil to physicians. The company portrayed the drug as having "remarkable efficacy and safety in the treatment of adolescent depression."

In fact, GSK's studies did not demonstrate that Paxil is effective in treating children and adolescents with major depressive disorder and showed the possibility of increased risk of suicidal thoughts and acts in adolescents. In documents submitted to the FDA and similar agencies in the United Kingdom and Europe, GSK admitted that its studies "all failed to separate[Paxil] from placebo overall and so do not provide strong evidence of efficacy in this indication."

Through these and other acts, GSK deprived physicians of the information they needed to evaluate the risks and benefits of prescribing Paxil for children and adolescents and deprived these youngsters of the benefit of their physicians' professional judgment.

Arthur Levin, Executive Director, Center for Medical Consumers, said: "The fact is that published drug studies are hugely biased towards good news — the drug works and is safe — and that studies reaching the opposite conclusion are likely never to see the light of day. The ability of drug companies to pick and choose the research they provide doctors in support of their product is an outrageous conflict of interest and puts us all in harm's way."



More than two million prescriptions for Paxil were written for children and adolescents in the United States in 2002. Nearly 900,000 of these prescriptions were for youngsters whose primary diagnosis was a mood disorder, the most common of which is depression. Prescriptions for Paxil to treat mood disorders in children and adolescents translated into US sales for GSK of approximately $55 million in 2002 alone.

In the last year, the use of Paxil for children and adolescents for the treatment of major depressive disorder has come under scrutiny by the FDA and regulatory agencies in the UK, Ireland, Europe and Canada. The FDA has advised caution in prescribing Paxil in children and adolescents for the treatment of major depressive disorder and is currently conducting an analysis of the data related to the use of Paxil and the possibility of increased suicidal thoughts. Regulatory agencies in the UK, Europe, Ireland and Canada have recommended that Paxil not be prescribed for adolescents and children with depression.

PART TWO - GARNIER COMES OUT FIGHTING COMING SOON

Copyright Paxil Protest

Paxil Protest Disclaimer of Liability
The user assumes all responsibility and risk for the use of this website and the Internet generally. Under no circumstances, including negligence, shall anyone involved in creating or maintaining this website, or shall the website owners or any of their directors, officers, employees or agents be liable for any direct, indirect, incidental, special or consequential damages, or lost profits that result from the use or inability to use the website and/or any other websites which are linked to this site.

Nor shall they be liable for any such damages including, but not limited to, reliance by a member or visitor on any information obtained via the website; or that result from mistakes, omissions, interruptions, deletion of files, viruses, errors, defects, or any failure of performance, communications failure, theft, destruction or unauthorized access.

All content on this website is provided to you on an “as is” and “as available” basis without warranty of any kind, either express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, and noninfringement.

Paxil Protest makes no warranty as to the accuracy, completeness, currency, or reliability of any content available through this website.

In states which do not allow some or all of the above limitations of liability, liability shall be limited to the greatest extent allowed by law.

Any information on this website may be removed without notice. Information may include technical inaccuracies or typographical errors. Furthermore, information posted at this website may change from time to time without notice.

Fair Use Notice
This may contain copyrighted (©) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.




ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Monday, June 01, 2009

BLAST FROM THE PAST - ROB ROBINSON PAXIL ACTIVIST

Here Rob wrote an open letter to GlaxoSmithKline employees.

The letter is taken from the website Rob created called Paxil Protest [now removed]

One has to admire Rob Robinson. If it wasn't for he, GlaxoSmithKline would still be raking in billions on the back of Paxil.

Rob stood up for what he believed in. He was counted.

Respect.

Fid

Author of Seroxat Sufferers Blog



Dear GlaxoSmithKline employee,

Few things in life are all good or all bad, and companies are no exception. GSK does do many things which have a positive impact on the world; however, that does not excuse the company for the unconscionable things it does.

This protest is not about the tens of thousands of GSK employees who are simply trying to:

do an honest day's work,
pay their bills on time,
raise a decent family,
and make a positive contribution to the world.

What this worldwide protest is about are dangerous and defective GlaxoSmithKline drugs — and a couple of white collar criminals, most notably:

J.P. Garnier, David Wheadon and Tadataka Yamada. These gentlemen are, at minimum, public relations liabilities for GSK. As such, company shareholders would be doing themselves, not to mention the public, a favor to get rid of them.

The Paxil debacle is not going away anytime soon, and company sacrifices to the altar of public opinion will be demanded as proof of penance.

UPDATE:

David Wheadon and Takeda Yamada left GlaxoSmithKline soon after our first protest in Philadelphia in September, 2005. Wheadon's current whereabouts are unknown, while Yamada has sought public relations refuge under cover of the philantropic umbrella of Bill Gates and his charitable foundation.

Glaxo's top brass will likely send out a series of internal memos in response to the GSK Worldwide Protest. We ask that you read carefully what the company "spin meisters" have say about all of this — and then to come back round to further consideration of the shocking truths exposed by this web site.

And while we would certainly appreciate your support ... we are not asking for it.

After all, when a company is under siege it is only natural for its employees to "close ranks." That said, we know the vast majority of Glaxo's employees are good people with a clear conscience and a sense of compassion. As such, we appeal to your basic human decency and knowing right from wrong when you see it.

Besides, the devastation and death spawned by Paxil (and many other defective GlaxoSmithKline drugs) could have and, indeed, might well have, happened to a member of your family — or that of your friends. The sinister reach of Paxil, in particular, extends into millions of medicine cabinets the world over; it is an "equal opportunity destroyer."

We are completely confident the evidence showcased at this site is an accurate reflection of the unvarnished truth. We are equally confident that GSK's version of, in particular, "the Paxilian reality" is one in which the company sent the truth on a fool's errand into a hall of mirrors — never to be seen again.

Are we wrong in our assessments? While you consider the evidence tendered, ask yourself a simple yet powerful question:

Why is GlaxoSmithKline not suing over what's said at this web site?

After all, if anything could potentially "damage the commercial profile" of Paxil and other GSK drugs — it's staring back out at you from your computer screen right now.

The reason the company doesn't sue is simple: Because it's all true. And because it's true: A lawsuit would turn what is, already, an exploding public relations disaster into a full blown catastrophe. It would result in the company's, most notably, confidential Paxil-related documents and intra-company communications being made public — thereupon exposing the spectacular fraud that is Paxil's legacy. GSK could, quite literally, put at risk all U.S. profits made from Paxil from the time the drug first began selling in 1992 if this fraud was exposed. (It is for this very reason that the company fought so hard to head off going to trial on May 2nd, 2005 in what would have been the world's first "Paxil withdrawal trial.")

If you are wondering "how could this have happened?" we encourage you to begin by reading Medicines out of Control? by Charles Medawar and Anita Hardon.

A public watchdog group out of the UK, Social Audit, introduces its web site with the following statement:

This website (Social Audit) began as an investigation of problems with antidepressant drugs — not only their adverse effects on many users, but also what the problem signaled about the conduct of the competent authorities, and the adequacy of their institutions and process. As the problem unfolded, notably between 1997 and 2003, it revealed a glimpse of pharmageddon — a world of sickness created and sustained by exploitation of the fear of disease, indifference to real health needs, dependence on authority, and misplaced trust in the triumph of drug benefits over harm.

These are the main themes in Medicines out of Control?

Kind Regards,
Rob Robinson, organizer
The GlaxoSmithKline Protest

ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING

Tuesday, November 13, 2007

GSK Children litigation - Canada vs Other Countries

This is too good an opportunity to miss. I'm unsure if the post will remain on Paxil Progress so I have reprinted here in its entirety.

To view the post click here

Here it is:

GSK Children litigation - Canada vs Other Countries

GSK has met with, and settled with many children who suffered side effects from paxil. The legal system in Canada stinks, and the lawyers won’t go up against the pharmaceuticals here. I know, I phoned every firm.

I obtained a high profile US lawyer. He is a wonderful man, one who is aware of the extent of suffering the children go through.

Last November (2006) was a very difficult month for my daughter. She had to meet with a GSK lawyer and discuss what she went through due to paxil. Before meeting with their lawyer we had a coffee with our US lawyer. My daughter does not like to discuss her paxil experience with anyone. She spoke with him openly, because she ‘knew’ he truly understood. She spoke about waking up each morning, her first thought being wanting to die. She would take a pin, something sharp and tear her skin. She rode her bicycle down stairs to harm herself. I won’t go on, you all get the picture…

Anyhow, at the end of the meeting I was asked what it would cost for private schooling to get her caught up-to-date. We discussed financial amounts. The GSK lawyer then turned to my daughter and said “we’re sorry this happened to you, but know it wasn’t done deliberately”. Ok, so that is where I spoke up. “Excuse me, don’t lie to her, GSK was very aware, the facts were hidden from the public, that’s why we’re here today”

GSK is aware I post on paxilprogress, but I was then asked if I personally knew Laurie Yorke, Rob Robertson, and Lisa Vansickle, as well as a few others I didn’t know of. “Hell yes!! Laurie is my adopted sister”, were family, as for Rob Robinson, sorry I could not afford the trip to the paxil protest.”

Interesting… what the hell does Laurie Yorke or Rob Robinson have to with my daughters suffering anyways? I shouldn’t have to lay out who I talk to, what we talk about, if it was via telephone, or in person. Anyway, we left the meeting and returned home. Since then, Skye researched schools she wished to attend when she received her settlement from GSK. She talks of going to New Jersey to meet Ryan, the desire to meet another child face to face that understands the suffering she went through.

A year has passed, Skye has received not a dime. Does anyone know why? Not because she hasn’t suffered or doesn’t deserve a settlement like the other children. But in paying her, they may have to pay other Canadian children. Once again it is all about the almighty dollar! They do not give a damn that they withheld information that ended up causing my child so much grief.

The following paragraph is for GSK, everyone that is in litigation with them have their posts from paxilprogress printed off. So by posting this here, I know they’ll get my message.

GSK, the pain and suffering a child suffers on paxil is the same, no matter the location. Place of birth should not matter. Saying that, my daughter’s father was born on US soil, because she resides with her mother in Canada should not make a difference.

I will continue doing what I am, I will provide for my childs needs. In the mean time, you paid her nothing. I am free to speak openly about GSK litigations. Why the hell would you meet with my child and make her rehash a horrific experience when you have no intention of doing anything about it? Was her experience not enough the first time around? How dare you play with my child’s emotions like that!!

Stay tuned, I need some closure to enable me to move on from this. A new website is in progress, one that will be getting media coverage, and will also be linked to every website available to me.
__________________
Rita

Tuesday, July 10, 2007

Improved Paxil Pediatric Settlement Hits "YouTube" Like a Bad Dream For Glaxo

Video Informs Parents That Clock Is Ticking On $48 Million Payback Fund; Unclaimed Money Will Revert Back to Drug Maker

Source: YubaNet.com

While the maker of Paxil and Paxil CR, GlaxoSmithKline (GSK), was required by law to announce the settlement terms of a parent-driven class action lawsuit in October 2006, it was not required to publicize the fact that those terms were greatly improved and simplified in April 2007. Because of legal actions taken by Public Citizen, many more parents whose children took Paxil before the age of 18 could benefit from the settlement if they only knew about it.

Public Citizen posted a YouTube video to tell these parents that there is a $48 million dollar fund created by GSK to pay them back. Even without receipts, parents can recover up to $100. Any money that is not claimed prior to the August 31, 2007 deadline will revert back to the drug company.

GSK and the FDA warned doctors only last year that Paxil increased suicidal thoughts in this age group, and yet this "popular" anti-depressant has been prescribed to children and teenagers since 1992. Parents believed this information was known and withheld by the company, which opted to settle the case rather than go to trial and be forced to answer some very difficult questions.

Watch the video, spread the word and help parents get the refund they deserve. Visit http://www.paxilpayback.org/

Monday, July 02, 2007

Psychiatrist indicted for fraud in Paxil trials

Source: KATC 3

Whose next?

Benbow?
Breckenridge?
Hudson?
Keller?

NEW ORLEANS -- Dr. Maria Carmen Palazzo was indicted by a federal grand jury on 55 counts of health care fraud and false documentation in connection with a clinical trial of Paxil in children and adolescents, U.S. Attorney Jim Letten said on Thursday.

The indictment alleges that during approximately a five-year period, Palazzo, 55, of New Orleans, defrauded Medicare in connection with services she claimed to have rendered to patients in a Psychiatric Partial Hospitalization Program at Touro Infirmary.

The indictment also charges that Palazzo defrauded Medicare by submitting fraudulent invoices to Touro for consulting and medical director services. The indictment says because of that Medicare paid Palazzo over $653,000 she was not entitled to receive.

Palazzo, who specializes in psychiatry, is also charged with offenses relating to clinical trials involving Paxil.

According to the indictment, Palazzo, as a clinical investigator for SmithKline Beecham doing business as GlaxoSmithKline, fraudulently failed to maintain and prepare records required by the FDA for evaluation the drug's safety and effectiveness in children and adolescents.

If convicted, Palazzo faces a maximum term of 445 years, and a fine of $10.15 million, Letten's office said.

Copyright 2007 The Associated Press. All rights reserved

Please contact me if you would like a guest post considered for publication on my blog.